Valuation : Insmed Incorporated

Market Cap 28.26B 24.35B 23.06B 20.9B 39.21B 2,700B 39.4B 274B 105B 1,374B 106B 104B 4,340B P/E 2026 *
-79.2x
P/E 2027 * 154x
Enterprise Value 27.63B 23.81B 22.54B 20.43B 38.33B 2,640B 38.52B 268B 103B 1,343B 104B 101B 4,243B EV / Sales 2026 *
15.3x
EV / Sales 2027 * 9.39x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day+1.67%
1 week+2.47%
Current month+6.23%
1 month-2.38%
3 months+33.80%
6 months-7.17%
Current year-25.64%
1 week 121.04
Extreme 121.035
130.83
1 month 117.15
Extreme 117.15
133.16
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Director of Finance/CFO 45 31/01/2020
Chief Tech/Sci/R&D Officer 62 19/12/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

Director

-5,000 0.0023%
10/08/26 Exercice

Chief Operating Officer

719,550 0.3320%
06/08/26 Exercice

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%+2.47%-11.23%+388.34% 28.27B
-2.11%-1.68%+44.52%+95.15% 66.93B
-0.23%-4.45%+30.39%+73.64% 61.97B
-1.05%-4.43%+30.56%+10.07% 24.59B
+0.34%-6.78%-7.27%-17.99% 24.3B
+0.43%-3.37%+14.85%-19.29% 19.41B
-3.03%-2.29%+185.12%+334.07% 16.77B
-1.94%-4.94%-5.29%+495.65% 14.18B
-2.28%-4.90%+43.64%+155.21% 13.91B
+3.24%-0.31%-5.65%+976.69% 14.01B
Average -0.50%-3.14%+31.96%+249.15% 28.43B
Weighted average by Cap. -0.64%-2.93%+31.53%+175.21%

Financials

2026 *2027 *
Net sales 1.81B 1.56B 1.47B 1.34B 2.51B 173B 2.52B 17.5B 6.73B 87.8B 6.78B 6.64B 277B 2.89B 2.49B 2.35B 2.13B 4B 276B 4.02B 27.96B 10.75B 140B 10.84B 10.6B 443B
Net income -349M -301M -285M -258M -485M -33.38B -487M -3.39B -1.3B -16.98B -1.31B -1.28B -53.66B 217M 187M 177M 160M 301M 20.73B 303M 2.1B 808M 10.55B 815M 797M 33.33B
Net Debt -632M -544M -515M -467M -876M -60.36B -881M -6.12B -2.35B -30.71B -2.37B -2.32B -97.04B -1.16B -997M -944M -855M -1.6B -110B -1.61B -11.21B -4.31B -56.22B -4.34B -4.25B -178B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
11/09/26 $129.41 +1.67% 1,698,268
10/09/26 $127.28 -1.18% 2,594,791
09/09/26 $128.80 +3.13% 2,841,960
08/09/26 $124.89 -1.11% 1,605,099
04/09/26 $126.29 -0.31% 1,802,693
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
129.41USD
Average target price
200.18USD
Spread / Average Target
+54.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!